Business Context and Reporting Period
This Form 8-K Current Report from Omeros Corporation covers events occurring on June 16, 2017, and June 21-22, 2017. The filing details the results of the 2017 Annual Meeting of Shareholders and the initiation of patent infringement litigation against generic drug manufacturers.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a report on corporate governance events and legal actions rather than financial results.
Material Changes and Events
Annual Meeting Results
Shareholders voted on five matters at the meeting held on June 16, 2017. Attendance represented 83.99% of outstanding shares.
- Director Elections: Thomas J. Cable and Peter A. Demopulos, M.D. were elected as Class II directors.
- Executive Compensation: Shareholders approved the advisory resolution regarding executive compensation.
- Compensation Vote Frequency: Shareholders voted to hold future advisory compensation votes every three years.
- 2017 Plan: Shareholders approved the 2017 Equity Incentive Plan.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
Patent Litigation
Omeros filed patent infringement lawsuits under the Hatch-Waxman Act against Sandoz Inc. (June 21, 2017) and Lupin Ltd. and Lupin Pharmaceuticals, Inc. (June 22, 2017). The suits allege infringement of six patents related to the drug OMIDRIA (phenylephrine and ketorolac injection).
- Patents Involved: U.S. Patent Nos. 8,173,707; 8,586,633; 9,066,856; 9,278,101; 9,399,040; and 9,486,406.
- Legal Consequence: The lawsuits trigger a 30-month stay on FDA approval of the defendants' Abbreviated New Drug Applications (ANDAs), expected to remain in effect until November 2019.
Guidance, Outlook, and Risks
Omeros intends to vigorously prosecute the infringement claims against Sandoz and Lupin, asserting that the defendants' challenges to patent validity lack merit. The filing includes standard forward-looking statements regarding the outcome of the lawsuits, noting that actual results may differ due to risks described in the company's Form 10-Q filed on May 15, 2017.
Investor Verification Checklist
- Verify the status of the 30-month stay on FDA approval for generic OMIDRIA versions by Sandoz and Lupin.
- Review the specific arguments made in the Paragraph IV Certifications filed by Sandoz and Lupin to assess the strength of Omeros' patent defense.
- Monitor the progress of the ongoing patent litigation against Par Pharmaceutical, Inc., as the assertions in the new lawsuits are noted to be substantially similar.
- Confirm the implementation timeline for the newly approved 2017 Equity Incentive Plan.